Burning Rock Biotech Ltd (nasdaq:BNR) Share Price

Company Profile

Business description
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.
Contact
No. 5, Xingdao Ring Road North
International Bio Island
Guangzhou510005
CHN
T: +86 2034037871
https://www.brbiotech.com
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
674

Recommended

Growth outlook solid, but upside more than priced in.

Shaun Ler | 19 October 2025

LNG project receives first commissioning gas.

Mark Taylor | 18 October 2025

Awaiting more info on robotaxis and lower cost models, here’s what we think of Tesla stock.

Seth Goldstein, CFA | 17 October 2025

Index	Last price	Change	% Change
All Ordinaries	9,305.20	21.40	0.23%
CAC 40	8,174.20	14.39	-0.18%
DAX 40	23,830.99	441.20	-1.82%
Dow JONES (US)	46,190.61	238.37	0.52%
FTSE 100	9,354.57	81.52	-0.86%
HKSE	25,859.44	612.34	2.43%
NASDAQ	22,679.97	117.44	0.52%
Nikkei 225	48,945.44	1,363.29	2.87%
NZX 50 Index	13,324.92	35.71	0.27%
S&P 500	6,664.01	34.94	0.53%
S&P/ASX 200	9,010.70	22.50	0.25%
SSE Composite Index	3,866.09	26.34	0.69%